T2 Biosystems, Inc. (TTOO)
After hours:
| Previous close | 3.6300 |
| Open | 3.8300 |
| Bid | 3.2200 x 400 |
| Ask | 3.2800 x 300 |
| Day's range | 3.2200 - 4.1800 |
| 52-week range | 2.6000 - 70.0000 |
| Volume | |
| Avg. volume | 319,686 |
| Market cap | 28.489M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
T2 Biosystems Announces Letter of Intent to Enter Strategic Partnership for Lyme Disease
Advances plan to launch T2Lyme Panel for detection of early Lyme diseaseFiled Pursuant to Rule 433Issuer Free Writing Prospectus dated May 6, 2024Relating to Preliminary Prospectus dated May 6, 2024Registration No. 333-278866 LEXINGTON, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has signed a non-binding letter of intent (“LOI”) to enter into a strat
- GlobeNewswire
T2 Biosystems Announces First Quarter 2024 Financial Results
Achieved double-digit growth in sepsis product revenue and reduced debt by approximately 80% compared to the prior year periodLEXINGTON, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced unaudited financial and operational results for the first quarter ended March 31, 2024. Recent Financial and Operational Highlights Achieved first quarter 2024 sep
- GlobeNewswire
T2 Biosystems Announces Commercial Expansion Through Middle East Distributor
Filed Pursuant to Rule 433 Issuer Free Writing Prospectus dated May 6, 2024 Relating to Preliminary Prospectus dated May 6, 2024 Registration No. 333-278866 LEXINGTON, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistant genes, today announced the execution of a territory exclusive distribution agreement in Qatar. Under the terms of the agreement, T2 Biosystems will sell T2Dx® Instruments,
